drugset
drugset / Trial / NCT06832189

EVR and EPO for Liver Transplant Tolerance

NCT06832189 ↗

Phase 1 Recruiting 20 enrolled National Institute of Allergy and Infectious Diseases (NIAID)
NaSingle-groupOpen-labelTreatment

Summary

This is an open label, single-arm, multicenter phase 1b study of stable adult liver transplant recipients on a tacrolimus (TAC)-based immunosuppression (IS) regimen who will transition from TAC to Everolimus (EVR), receive five doses of EPO and concurrently initiate phased withdrawal from EVR. The primary objective is to test the safety of administering Everolimus (EVR) and epoetin alfa (EPO) to induce operational tolerance in stable adult liver transplant recipients

Timeline

Start
2026-01-21
Primary completion
2030-06-01
Completion
2030-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule 1 mg Oral
Subject Everolimus Small molecule 2 mg Oral
Subject Everolimus Small molecule 3 mg Oral
Subject epoetin alfa Protein / enzyme biologic 10000 iu Subcutaneous

Indications

No indication recorded.